Filing Flows › Xeris Biopharma Holdings (XERS) › Stock forecast & fair value
Xeris Biopharma Holdings (XERS) stock forecast and price target
Xeris Biopharma Holdings (XERS) trades at $15.20. 7 analysts' median price target is $12.00 (-21%), from $8.00 to $18.00.
Xeris Biopharma Holdings' latest quarter
Xeris Biopharma Holdings, Q3 2026: revenue $107M (+44% year over year), operating margin 15.8%, net earnings $11.3M, operating cash flow $35.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for XERS stock?
The median of 7 analysts' 12-month targets is $12.00, -21% from $15.20; the range is $8.00 to $18.00. The average rating is none.
Does Xeris Biopharma Holdings usually beat earnings estimates?
It beat the consensus EPS estimate in 60% of the quarters on record.
Is XERS stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.